IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging (MRI) compatible medical devices and accessories and services. It also provides non-magnetic Intravenous (IV) infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IRMD
Previous Symbol
CUSIPN/A
Phone407-677-8022
Debt
Debt-to-Equity RatioN/A
Current Ratio8.91
Quick Ratio8.01
Price-To-Earnings
Trailing P/E Ratio337.75
Forward P/E Ratio69.28
P/E GrowthN/A
Sales & Book Value
Annual Sales$23.08 million
Price / Sales12.80
Cash Flow$0.2125 per share
Price / Cash Flow127.14
Book Value$3.12 per share
Price / Book8.66
Profitability
EPS (Most Recent Fiscal Year)$0.08
Net Income$490,000.00
Net Margins16.59%
Return on Equity11.72%
Return on Assets9.95%
Miscellaneous
Employees83
Outstanding Shares10,930,000
Market Cap$299.49 million
OptionableNot Optionable
Iradimed (NASDAQ:IRMD) Frequently Asked Questions
What is Iradimed's stock symbol?
Iradimed trades on the NASDAQ under the ticker symbol "IRMD."
How will Iradimed's stock buyback program work?
Iradimed declared that its board has authorized a share repurchase plan on Sunday, June 4th 2017, which permits the company to buyback $8,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to purchase shares of its stock through open market purchases. Shares buyback plans are typically a sign that the company's board of directors believes its shares are undervalued.
How were Iradimed's earnings last quarter?
Iradimed Corp (NASDAQ:IRMD) announced its quarterly earnings data on Tuesday, October, 30th. The medical equipment provider reported $0.14 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.10 by $0.04. The medical equipment provider had revenue of $7.62 million for the quarter, compared to analyst estimates of $7.43 million. Iradimed had a net margin of 16.59% and a return on equity of 11.72%. View Iradimed's Earnings History.
When is Iradimed's next earnings date?
What guidance has Iradimed issued on next quarter's earnings?
Iradimed issued an update on its FY 2018 earnings guidance on Tuesday, October, 30th. The company provided earnings per share guidance of $0.50-0.51 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.47. The company issued revenue guidance of $30-30.2 million, compared to the consensus revenue estimate of $30.23 million.Iradimed also updated its Q4 2018 guidance to $0.12-0.13 EPS.
What price target have analysts set for IRMD?
1 Wall Street analysts have issued 1 year target prices for Iradimed's stock. Their predictions range from $35.00 to $35.00. On average, they anticipate Iradimed's stock price to reach $35.00 in the next year. This suggests a possible upside of 29.5% from the stock's current price. View Analyst Price Targets for Iradimed.
What is the consensus analysts' recommendation for Iradimed?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iradimed in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iradimed.
Has Iradimed been receiving favorable news coverage?
News stories about IRMD stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Iradimed earned a daily sentiment score of 0.7 on InfoTrie's scale. They also gave media stories about the medical equipment provider a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days.
Who are some of Iradimed's key competitors?
Some companies that are related to Iradimed include AtriCure (ATRC), Cryolife (CRY), Orthofix Medical (OFIX), Cardiovascular Systems (CSII), Tactile Systems Technology (TCMD), Intersect ENT (XENT), AngioDynamics (ANGO), SurModics (SRDX), Cerus (CERS), OraSure Technologies (OSUR), LeMaitre Vascular (LMAT), Inovio Pharmaceuticals (INO), Antares Pharma (ATRS), Axonics Modulation Technologies (AXNX) and SI-Bone (SIBN).
Who are Iradimed's key executives?
Iradimed's management team includes the folowing people:
- Roger Susi, Chairman, President & Chief Executive Officer
- John McCreery, Chief Operating Officer
- Christopher K. Scott, Chief Financial & Accounting Officer, Secretary
- Louis Waldman, Controller
- Brent Johnson, Executive VP-Worldwide Sales & Marketing
Who are Iradimed's major shareholders?
Iradimed's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.09%), Vanguard Group Inc. (2.29%), Vanguard Group Inc (2.29%), Renaissance Technologies LLC (1.82%), Mondrian Investment Partners LTD (1.09%) and Cadence Capital Management LLC (0.68%). Company insiders that own Iradimed stock include Christopher K Scott, Francis X Casey, John K Mccreery, Louis S Waldman, Monty K Allen, Roger E Susi and Steven M Nardi. View Institutional Ownership Trends for Iradimed.
Which institutional investors are selling Iradimed stock?
IRMD stock was sold by a variety of institutional investors in the last quarter, including Cadence Capital Management LLC, Mondrian Investment Partners LTD, Russell Investments Group Ltd., Neuberger Berman Group LLC, Connors Investor Services Inc., Macquarie Group Ltd. and Federated Investors Inc. PA. Company insiders that have sold Iradimed company stock in the last year include Christopher K Scott, Francis X Casey, John K Mccreery, Louis S Waldman, Monty K Allen and Steven M Nardi. View Insider Buying and Selling for Iradimed.
Which institutional investors are buying Iradimed stock?
IRMD stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Vanguard Group Inc, Vanguard Group Inc., EAM Global Investors LLC, EAM Investors LLC, Walthausen & Co. LLC and Caxton Associates LP. View Insider Buying and Selling for Iradimed.
How do I buy shares of Iradimed?
Shares of IRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Iradimed's stock price today?
One share of IRMD stock can currently be purchased for approximately $27.02.
How big of a company is Iradimed?
Iradimed has a market capitalization of $299.49 million and generates $23.08 million in revenue each year. The medical equipment provider earns $490,000.00 in net income (profit) each year or $0.08 on an earnings per share basis. Iradimed employs 83 workers across the globe.
What is Iradimed's official website?
How can I contact Iradimed?
Iradimed's mailing address is 1025 Willa Springs Dr., Winter Springs FL, 32708. The medical equipment provider can be reached via phone at 407-677-8022 or via email at [email protected]
MarketBeat Community Rating for Iradimed (NASDAQ IRMD)
MarketBeat's community ratings are surveys of what our community members think about Iradimed and other stocks. Vote "Outperform" if you believe IRMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
